Organogenesis $ORGO Shares Bought by SG Americas Securities LLC

SG Americas Securities LLC increased its position in Organogenesis (NASDAQ:ORGO) by 39.8% in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 790,766 shares of the company’s stock after acquiring an additional 225,265 shares during the period. SG Americas Securities LLC’s holdings in Organogenesis were worth $1,874,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors have also added to or reduced their stakes in ORGO. Quarry LP acquired a new position in shares of Organogenesis in the third quarter valued at about $25,000. Flagship Harbor Advisors LLC acquired a new stake in shares of Organogenesis during the fourth quarter worth about $34,000. Federated Hermes Inc. lifted its holdings in shares of Organogenesis by 52.8% during the fourth quarter. Federated Hermes Inc. now owns 8,541 shares of the company’s stock worth $44,000 after purchasing an additional 2,953 shares during the period. Walleye Capital LLC purchased a new stake in Organogenesis in the second quarter valued at approximately $45,000. Finally, Mercer Global Advisors Inc. ADV purchased a new stake in Organogenesis in the fourth quarter valued at approximately $57,000. Hedge funds and other institutional investors own 49.57% of the company’s stock.

Organogenesis Price Performance

Shares of NASDAQ ORGO opened at $2.36 on Friday. The company has a debt-to-equity ratio of 0.05, a quick ratio of 3.16 and a current ratio of 3.53. The firm has a fifty day moving average of $2.45 and a 200 day moving average of $3.19. The firm has a market cap of $303.68 million, a PE ratio of -12.42 and a beta of 1.33. Organogenesis has a one year low of $2.04 and a one year high of $7.08.

Organogenesis (NASDAQ:ORGO) last posted its quarterly earnings data on Thursday, May 7th. The company reported ($0.37) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.29) by ($0.08). Organogenesis had a negative net margin of 0.84% and a positive return on equity of 9.63%. The company had revenue of $37.23 million for the quarter, compared to analysts’ expectations of $43.26 million.

Analysts Set New Price Targets

A number of research firms have issued reports on ORGO. BTIG Research lowered shares of Organogenesis from a “buy” rating to a “neutral” rating in a research report on Friday, May 8th. Wall Street Zen raised shares of Organogenesis from a “strong sell” rating to a “sell” rating in a report on Saturday, June 20th. Truist Financial began coverage on shares of Organogenesis in a research note on Thursday, May 28th. They issued a “hold” rating and a $3.00 price objective on the stock. UBS Group set a $3.00 target price on shares of Organogenesis in a report on Thursday, May 28th. Finally, Weiss Ratings downgraded shares of Organogenesis from a “hold (c)” rating to a “sell (d)” rating in a research report on Monday, May 11th. One equities research analyst has rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, Organogenesis currently has an average rating of “Hold” and an average price target of $5.75.

Organogenesis Profile

Organogenesis Inc operates as a regenerative medicine company focused on the development, manufacturing and commercialization of therapeutic solutions for wound care, surgical repair and sports medicine. The company’s product portfolio addresses a range of acute and chronic tissue repair needs, leveraging bioengineered skin substitutes, human placental-derived products and other allografts designed to promote healing and reduce scarring. Organogenesis markets its therapies to hospitals, outpatient clinics, wound care centers and other healthcare providers.

Key offerings include Apligraf, a living skin substitute for treatment of diabetic foot ulcers and venous leg ulcers; Dermagraft, a cryopreserved human fibroblast-derived dermal substitute; Grafix, a placental membrane allograft for complex and chronic wounds; and TheraSkin, a cryopreserved human skin allograft used in surgical and reconstructive procedures.